Almotriptan

drugbox
IUPAC_name = N,N-dimethyl-2- [5-(pyrrolidin-1-ylsulfonylmethyl)- 1H-indol-3-yl] -ethanamine

---

width = 250px
CAS_number = 154323-57-6
ATC_prefix = N02
ATC_suffix = CC05
ATC_supplemental =
PubChem = 123606
DrugBank = APRD00169
C=17 | H=25 | N=3 | O=2 | S=1
molecular_weight = 335.465 g/mol
bioavailability = 70%
protein_bound = 35%
metabolism =
elimination_half-life = 3-4 hours
pregnancy_category = C(USA)
legal_status = Prescription only
routes_of_administration =Oral

Almotriptan (Axert®, Almogran®) is a triptan drug discovered by Almirall Prodesfarma and licensed to Ortho-McNeil for the treatment of migraine headaches. It is available in strengths of 6.25 and 12.5 mg as a tablet.

In the United States and Canada almotriptan is available under the name Axert® only by prescription. AXERT® for oral administration contains almotriptan malate equivalent to 6.25 or 12.5 mg of almotriptan. Each compressed tablet contains the following inactive ingredients: mannitol, cellulose, povidone, sodium starch glycolate, sodium stearyl fumarate, titanium dioxide, hypromellose, polyethylene glycol, propylene glycol, iron oxide (6.25 mg only), FD&C Blue No. 2 (12.5 mg only), and carnauba wax.The brand Almogran is used in Belgium, Finland, France, Germany, Italy, Portugal, Spain and the United Kingdom. Each 12.5 mg. tablet contains the following inactive ingredients: carnauba wax, hypromellose, indigo carmine (E132), macrogol 400, mannitol, microcrystalline cellulose, povidone, propylene glycol, sodium starch glycollate, sodium stearyl fumarate and titanium dioxide (E171).

Clinical uses

Almotriptan is indicated for the acute treatment of migraine with or without aura in adults.

External links

* [http://www.almirall.es/almirall/cda/nav_eng/03/0303.jsp R&D page] by Almirall Prodesfarma
* [http://www.axert.com Axert] Official homepage by Ortho-McNeil
* [http://www.axert.com/axert/assets/axertpi.pdf Axert] prescribing information